{'fraction_non_alphanumeric': 0.0165892501658925, 'fraction_numerical': 0.0033178500331785005, 'mean_word_length': 5.032, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An Insight in Biomarkers for Colorectal Cancer

Colorectal cancer is a leading cause of death worldwide which affects the parts of digestive system. It is considered as third most common cancer in the world. The incidence of colorectal cancer is strongly linked to so call western lifestyle. Incidence is increases with age and is higher in men than women. Most of the colorectal cases are sporadic and develop in individual patients slowly. However, its hereditary aetiology is also well established. There are several methodologies for treatments are employed although none of them provide complete prevention from colorectal cancer. By advances in medical imaging technology early and accurate diagnosis of metastatic lesions is now possible. The treatment roadmaps followed are surgery, neoadjuvant radiotherapy and adjuvant chemotherapy. The resection of lung, liver and other organ metastases is required for patient survival when and is followed by other treatment and rigorous follow up regimen. In patients with advance stage of cancer (stage III/ IV) adjuvant chemotherapy is followed to increase the life expectancy of patients. It’s a dreadful full disease with high mortality rate. 5 year survival rate is 90% in stage I and approximately 10% in stage IV patients. The regular screening of a person can reduce incidence as well as mortality from colorectal cancer. However, due to economic concern and lack of awareness regular screening programmes are not implemented in most of the countries.